Search results for "AMYLOID"

showing 10 items of 494 documents

The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10

2012

The in vivo roles of meprin metalloproteases in pathophysiological conditions remain elusive. Substrates define protease roles. Therefore, to identify natural substrates for human meprin α and β we employed TAILS (terminal amine isotopic labeling of substrates), a proteomics approach that enriches for N-terminal peptides of proteins and cleavage fragments. Of the 151 new extracellular substrates we identified, it was notable that ADAM10 (a disintegrin and metalloprotease domain-containing protein 10)—the constitutive α-secretase—is activated by meprin β through cleavage of the propeptide. To validate this cleavage event, we expressed recombinant proADAM10 and after preincubation with meprin…

Proteomicsalpha-2-HS-Glycoproteinmedicine.medical_treatmentADAM10ADAM10 ProteinMice0302 clinical medicine610 Medicine & healthMice KnockoutExtracellular Matrix Proteins0303 health sciencesMetalloproteinaseDegradomeMetalloendopeptidasesMeprinADAM10Terminal amine isotopic labeling of substratesADAM ProteinsElafinBiochemistryTAILSCytokinesMolecular MedicineElafinResearch Article610 Medicine & healthBiologyCell Line03 medical and health sciencesCellular and Molecular NeurosciencemedicineDisintegrinAnimalsHumansAmino Acid SequenceCystatin CMolecular Biology030304 developmental biologyPharmacologyProteaseMeprin; ADAM10; Metalloproteases; Proteomics; TAILS; DegradomeMembrane ProteinsCell BiologyADAM ProteinsHEK293 CellsMembrane proteinbiology.proteinMetalloproteases570 Life sciences; biologyAmyloid Precursor Protein SecretasesCaco-2 Cells030217 neurology & neurosurgery
researchProduct

Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.

2012

We present an integrated approach to identify and optimize a novel class of γ-secretase modulators (GSMs) with a unique pharmacological profile. Our strategy included (i) virtual screening through application of a recently developed protocol (PhAST), (ii) synthetic chemistry to discover structure–activity relationships, and (iii) detailed in vitro pharmacological characterization. GSMs are promising agents for treatment or prevention of Alzheimer’s disease. They modulate the γ-secretase product spectrum (i.e., amyloid-β (Aβ) peptides of different length) and induce a shift from toxic Aβ42 to shorter Aβ species such as Aβ38 with no or minimal effect on the overall rate of γ-secretase cleavag…

PyridinesPyridonesMolecular Sequence DataPeptideComputational biologyCHO CellsBiochemistryStructure-Activity RelationshipAlzheimer DiseaseCricetinaeAnimalsHumansγ secretaseAmino Acid Sequencechemistry.chemical_classificationVirtual screeningActivity profileAmyloid beta-PeptidesChemistryGeneral MedicineIntegrated approachIn vitroMinimal effectDrug DesignMolecular MedicineAmyloid Precursor Protein SecretasesACS chemical biology
researchProduct

Amyloid-Beta Induces Different Expression Pattern of Tissue Transglutaminase and Its Isoforms on Olfactory Ensheathing Cells: Modulatory Effect of In…

2021

Abstract Alzhèimer Disease (AD) is characterized by protein aggregates in the brain, including amyloid-beta (Aβ), a substrate for tissue transglutaminase (TG2). We assessed the effect of full native peptide of Aβ (1–42), the fragments (25–35 and 35–25) on TG2 expression and its isoforms (Long and Short) on mouse Olfactory Ensheathing Cells (OECs). The levels of cytoskeletal proteins, Vimentin and Glial Fibrillary Acid Protein, were also studied. The effect of the pre-treatment with Indicaxanthin on cell viability, total Reactive Oxygen Species, superoxide anion and apoptotic pathway activation was assessed. Since Nestin is co-expressed in pluripotent stem cells with cyclin D1, their levels …

Pyridinestissue transglutaminase; olfactory ensheathing cells; amyloid-beta; oxidative stress; Indicaxanthin; self-renewalApoptosisAmyloid‐betaIndicaxanthinVimentinself-renewallcsh:ChemistryNestinMicechemistry.chemical_compoundProtein IsoformsCyclin D1lcsh:QH301-705.5SpectroscopybiologySuperoxideOpuntiaCell DifferentiationGeneral MedicineOlfactory Bulbamyloid-betaBetaxanthinsComputer Science ApplicationsCell biologyIndicaxanthinAmyloid betaTissue transglutaminase; Olfactory Ensheathing Cells; Amyloid-Beta; oxidative stress; In-dicaxanthin; self-renewalArticleGene Expression Regulation EnzymologicCatalysisInorganic ChemistryCyclin D1Alzheimer DiseaseGTP-Binding ProteinsGlial Fibrillary Acidic ProteinAnimalsHumansVimentinProtein Glutamine gamma Glutamyltransferase 2Viability assayPhysical and Theoretical ChemistryMolecular BiologyAmyloid beta-PeptidesTransglutaminasesOrganic ChemistryTissue transglutaminaseNestinSelf‐renewalNerve Regenerationlcsh:Biology (General)lcsh:QD1-999chemistryOxidative stressOlfactory ensheathing cellsbiology.proteinOlfactory ensheathing gliaReactive Oxygen SpeciesInternational Journal of Molecular Sciences
researchProduct

Amyloid Beta-Mediated Changes in Synaptic Function and Spine Number of Neocortical Neurons Depend on NMDA Receptors

2021

Onset and progression of Alzheimer’s disease (AD) pathophysiology differs between brain regions. The neocortex, for example, is a brain region that is affected very early during AD. NMDA receptors (NMDARs) are involved in mediating amyloid beta (Aβ) toxicity. NMDAR expression, on the other hand, can be affected by Aβ. We tested whether the high vulnerability of neocortical neurons for Aβ-toxicity may result from specific NMDAR expression profiles or from a particular regulation of NMDAR expression by Aβ. Electrophysiological analyses suggested that pyramidal cells of 6-months-old wildtype mice express mostly GluN1/GluN2A NMDARs. While synaptic NMDAR-mediated currents are unaltered in 5xFAD …

QH301-705.5Amyloid betasomatosensory cortexDendritic SpinesMice TransgenicNeocortexSomatosensory systemReceptors N-Methyl-D-AspartateCatalysisArticleInorganic ChemistryAlzheimer Diseasemental disordersmedicineAnimalsBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyNeuronsNeocortexAmyloid beta-PeptidesbiologyPyramidal Cellsmusculoskeletal neural and ocular physiologyOrganic ChemistryWild typeAmyloid betaExcitatory Postsynaptic PotentialsGeneral Medicine5xFADPathophysiologyComputer Science ApplicationsNMDARChemistryElectrophysiologyProtein Subunitsmedicine.anatomical_structurenervous systemKnockout mouseSynapsesbiology.proteinNMDA receptorbiological phenomena cell phenomena and immunityNeuroscienceAlzheimer’s diseasepsychological phenomena and processesInternational Journal of Molecular Sciences
researchProduct

Left ventricular hypertrophy or storage disease? the incremental value of speckle tracking strain bull's-eye

2017

Left ventricular hypertrophy (LVH) develops in response to a variety of physical, genetic, and biochemical stimuli and represents the early stage of ventricular remodeling. In patients with LVH, subclinical left ventricular (LV) dysfunction despite normal ejection fraction (EF) may be present before the onset of symptoms, which portends a dismal prognosis. Strain measurement with two-dimensional speckle tracking echocardiography (STE) represents a highly reproducible and accurate alternative to LVEF determination. The present review focuses on current available evidence that supports the incremental value of STE in the diagnostic and prognostic workup of LVH. When assessing the components o…

Radiology Nuclear Medicine and ImagingSpeckle tracking echocardiographyDisease030204 cardiovascular system & hematologyLeft ventricular hypertrophytwo-dimensional strain0302 clinical medicineCardiomegaly Exercise-Induced030212 general & internal medicineanabolic steroidSubclinical infectionamyloidosiEvidence-Based MedicineEjection fractionHypertrophic cardiomyopathyleft ventricular hypertrophyEchocardiographyCardiologyElasticity Imaging TechniquesHypertrophy Left VentricularRadiologyCardiomyopathiesCardiology and Cardiovascular MedicineHumanendocrine systemmedicine.medical_specialtyarterial hypertensionReproducibility of ResultSensitivity and SpecificityDiagnosis Differential03 medical and health sciencesElasticity Imaging TechniqueInternal medicinemedicineathlete's heartHumanscardiovascular diseasesVentricular remodelingspeckle tracking echocardiographyCardiomyopathiebusiness.industryReproducibility of ResultsStroke Volumeaortic stenosiImage Enhancementmedicine.diseasehypertrophic cardiomyopathyDifferential diagnosisMetabolism Inborn ErrorbusinessMetabolism Inborn Errors
researchProduct

Alcadein cleavages by amyloid beta-precursor protein (APP) alpha- and gamma-secretases generate small peptides, p3-Alcs, indicating Alzheimer disease…

2009

Alcadeins (Alcs) constitute a family of neuronal type I membrane proteins, designated Alc(alpha), Alc(beta), and Alc(gamma). The Alcs express in neurons dominantly and largely colocalize with the Alzheimer amyloid precursor protein (APP) in the brain. Alcs and APP show an identical function as a cargo receptor of kinesin-1. Moreover, proteolytic processing of Alc proteins appears highly similar to that of APP. We found that APP alpha-secretases ADAM 10 and ADAM 17 primarily cleave Alc proteins and trigger the subsequent secondary intramembranous cleavage of Alc C-terminal fragments by a presenilin-dependent gamma-secretase complex, thereby generating "APP p3-like" and non-aggregative Alc pe…

Receptors Cell SurfaceADAM17 ProteinBiochemistryPresenilinCell LineADAM10 ProteinAmyloid beta-Protein PrecursorMiceAlzheimer Diseasemental disordersAmyloid precursor proteinmedicineAnimalsHumansReceptorMolecular BiologyPeptide sequencechemistry.chemical_classificationbiologyProtein Synthesis Post-Translational Modification and DegradationCalcium-Binding ProteinsMembrane ProteinsCell Biologymedicine.diseaseMolecular biologyAmino acidProtease NexinsADAM ProteinsMembrane proteinchemistrybiology.proteinAlzheimer's diseaseAmyloid Precursor Protein SecretasesPeptidesAmyloid precursor protein secretaseThe Journal of biological chemistry
researchProduct

2014

In the pathogenesis of Alzheimer’s disease (AD) the homeostasis of amyloid precursor protein (APP) processing in the brain is impaired. The expression of the competing proteases ADAM10 (a disintegrin and metalloproteinase 10) and BACE-1 (beta site APP cleaving enzyme 1) is shifted in favor of the A-beta generating enzyme BACE-1. Acitretin–a synthetic retinoid–e.g., has been shown to increase ADAM10 gene expression, resulting in a decreased level of A-beta peptides within the brain of AD model mice and thus is of possible value for AD therapy. A striking challenge in evaluating novel therapeutically applicable drugs is the analysis of their potential to overcome the blood-brain barrier (BBB)…

Reporter geneMultidisciplinarybiologyADAM10TransfectionPharmacologyBlood–brain barriermedicine.anatomical_structureBeta-secretase 1Targeted drug deliverymedicinebiology.proteinAmyloid precursor proteinAmyloid precursor protein secretasePLOS ONE
researchProduct

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

2015

Abstract Background: Familial amyloid polyneuropathy related to transthyretin gene (TTR-FAP) is a life-threatening disease transmitted as an autosomal dominant trait. Val30Met mutation accounts for the majority of the patients with large endemic foci especially in Portugal, Sweden and Japan. However, more than one hundred other mutations have been described worldwide. A great phenotypic variability among patients with late- and early-onset has been reported. Objective: To present a detailed report of TTR-FAP patients diagnosed in our tertiary neuromuscular center, in a 20-year period. Methods: Clinical informations were gathered through the database of our center. Results: The study involve…

Research ReportPediatricsmedicine.medical_specialtyPathologydysautonomiaCardiomyopathyLate onsetTTRtransthyretinmedicineFamilial amyloid polyneuropathy FAP transthyretin TTR amyloidosis cardiomyopathy dysautonomia epidemiology Italyamyloidosisbiologybusiness.industryAmyloidosisDysautonomiaAutosomal dominant traitFAPmedicine.diseaseTransthyretinPeripheral neuropathyNeurologyItalyFamilial amyloid polyneuropathybiology.proteinepidemiologyNeurology (clinical)medicine.symptombusinessPolyneuropathycardiomyopathyJournal of Neuromuscular Diseases
researchProduct

RNAs That Behave Like Prions

2020

The term “prion” was originally coined to describe the proteinaceous infectious agents involved in mammalian neurological disorders. More recently, a prion has been defined as a nonchromosomal, protein-based genetic element that is capable of converting the copies of its own benign variant into the prion form, with the new phenotypic effects that can be transmitted through the cytoplasm. Some prions are toxic to the cell, are able to aggregate and/or form amyloid structures, and may be infectious in the wild, but none of those traits are seen as an integral property of all prions. We propose that the definition of prion should be expanded, to include the inducible transmissible entities und…

RiboswitchMolecular Biology and PhysiologyAmyloidProtein ConformationPrionsanimal diseaseslcsh:QR1-502viroidsPiwi-interacting RNApiRNABiologyribozymesMicrobiologylcsh:Microbiology03 medical and health sciencesMice0302 clinical medicineAnimalsHumansRibozymesprionsMolecular Biology030304 developmental biologyGenetics0303 health sciencesRibozymeRNAOpinion/HypothesisPhenotypeViroidsQR1-502nervous system diseasesCytoplasmbiology.proteinGenetic elementRNA030217 neurology & neurosurgerymSphere
researchProduct

Curcumin as Scaffold for Drug Discovery against Neurodegenerative Diseases

2021

Neurodegenerative diseases (NDs) are one of major public health problems and their impact is continuously growing. Curcumin has been proposed for the treatment of several of these pathologies, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) due to the ability of this molecule to reduce inflammation and aggregation of involved proteins. Nevertheless, the poor metabolic stability and bioavailability of curcumin reduce the possibilities of its practical use. For these reasons, many curcumin derivatives were synthetized in order to overcome some limitations. In this review will be highlighted recent results on modification of curcumin scaffold in the search of new effective therap…

ScaffoldDrug discoverybusiness.industryMedicine (miscellaneous)amyloidSettore CHIM/06 - Chimica OrganicaReviewDiseaseMetabolic stabilityBioinformaticsGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundchemistrylcsh:Biology (General)CurcuminMedicinecurcumintaubusinessAlzheimer’s diseaselcsh:QH301-705.5Biomedicines
researchProduct